UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Protalix Bio Therapeutics Inc.
(Name of Issuer)
Common Stock, par value US$ 0.001 per Share
(Title of Class of Securities)
74365A309
(CUSIP Number)
March 18, 2020
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the Act.
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
|
Angels Investments in Hi Tech Ltd
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
|
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Israel
|
|
|
|||
|
|
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
3,288,091 common shares
|
|
|
|||
|
|
|
||||
|
6
|
SHARED VOTING POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
3,288,091 common shares
|
|
|
|||
|
|
|
||||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
|
9.9%
|
|
|
|||
|
|
|
||||
|
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
|
CO
|
|
|
|||
|
|
|
||||
Page 2 of 5 Pages
|
Item 1(a)
|
Name of Issuer
Protalix Bio Therapeutics Inc. (the "Issuer").
|
|
Item 1(b)
|
Address of Issuer's Principal Executive Offices
2 Snunit Street, Science Partk POB 455 Carmiel 2161401, Israel
|
Item 2(a)-(b) Name of Person Filing; Address of Principal Business Office or, if none, Residence
| (a) |
Angels Investments in Hi Tech Ltd. (“Angels”)
C/O Marius Nacht
“Reporting Person”
From 42 Brandeis St. Tel Aviv 6200157, Israel
|
|
Item 2(c)
|
Citizenship
Angels is incorporated under the laws of Israel. Marius Nacht who is sole shareholder and director of Angels is an Israeli citizen.
|
|
Item 2(d)
|
Title of Class of Securities
|
|
Item 2(e)
|
CUSIP Number
|
| Item 3 |
If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
Not applicable.
|
| Item 4 |
Ownership
|
| (a) |
Amount beneficially owned: 3,288,091(1)
|
| (b) |
Percent of Class: 9.9% (2)
|
| (c) |
Number of shares as to which the person has:
|
| (i) |
Sole power to vote or direct the vote: 3,288,091(1)
|
| (ii) |
Shared power to vote or to direct the vote: 0
|
| (iii) |
Sole power to dispose or to direct the disposition of: 3,288,091(1)
|
| (iv) |
Shared power to dispose or to direct the disposition of :0
|
| (1) |
The number of ordinary shares set forth above includes (i) 2,816,901 common shares of Protalix Bio Therapeutics, Inc (the “Issuer”), par value $0.001 per share (“Common Shares”) and (ii) 471,190 Common Shares issuable upon the exercise
of currently exercisable warrants.
|
| (2) |
All Share percentage calculation are based on (i) 32,442,636 Common Shares outstanding as of March 18, 2020, as reported by the Issuer to the reporting Persons and (ii) 471,190 Common Shares issuable upon the exercise of currently
exercisable warrants, which are treated as issued and outstanding solely for the purpose of computing the percentage ownership of the Reporting Person pursuant to Rule 13d-3(d)(1)(i) under the Act.
|
Page 3 of 5 Pages
| Item 5 |
Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the following: ☐
|
| Item 6 |
Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
|
| Item 7 |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
Not applicable.
|
| Item 8 |
Identification and Classification of Members of the Group
Not applicable.
|
| Item 9 |
Notice of Dissolution of Group
Not applicable.
|
| Item 10 |
Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with
the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
Page 4 of 5 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Dated: November 23, 2020
|
ANGELS INVESTMENTS IN HI TECH LTD.
By: /s/ Marius Nacht
MARIUS NACHT
Sole Shareholder
|
Page 5 of 5 Pages